GLP-1 Agonists Show Promise for Acute Stroke Treatment and Prevention

Stroke, particularly Acute Ischemic Stroke (AIS), remains a leading cause of death and long-term disability globally, with limited therapeutic options for neuroprotection and secondary prevention. Current treatments often focus on reperfusion, but there's a critical need for strategies that can mitigate neuronal damage and prevent recurrence. This review addresses the potential of GLP-1 Receptor Agonists (GLP-1 RAs) to offer neuroprotective and cardiovascular benefits in the context of stroke, exploring their mechanisms beyond glycemic control.

The review highlighted consistent neuroprotective effects of GLP-1 RAs in preclinical models, demonstrating significant reductions in infarct volume and improvements in neurological outcomes. For instance, studies showed a 25-40% reduction in infarct size and a 30-50% improvement in neurological deficit scores when GLP-1 RAs were administered post-ischemia. These benefits are attributed to anti-inflammatory, anti-apoptotic, and pro-angiogenic mechanisms. In clinical settings, while direct stroke treatment data is emerging, large cardiovascular outcome trials (CVOTs) consistently reported a 15-20% reduction in major adverse cardiovascular events (MACE), including a significant 10-16% reduction in non-fatal stroke incidence in patients with type 2 diabetes and high cardiovascular risk. GLP-1 RAs also improved endothelial function and reduced systemic inflammation. > The most compelling finding is the consistent evidence from large-scale clinical trials demonstrating a significant reduction in the risk of recurrent stroke in high-risk patients treated with GLP-1 RAs, underscoring their potential for secondary prevention.